Edition:
United States

NxStage Medical Inc (NXTM.O)

NXTM.O on Nasdaq

25.65USD
11:37am EST
Change (% chg)

$-0.37 (-1.42%)
Prev Close
$26.02
Open
$26.09
Day's High
$26.17
Day's Low
$25.58
Volume
130,918
Avg. Vol
864,776
52-wk High
$30.80
52-wk Low
$20.45

Latest Key Developments (Source: Significant Developments)

NXSTAGE SAYS STOCKHOLDER APPROVE MERGER WITH FRESENIUS MEDICAL CARE
Friday, 27 Oct 2017 12:10pm EDT 

Oct 27 (Reuters) - NxStage Medical ::NXSTAGE ANNOUNCES STOCKHOLDER APPROVAL OF MERGER AGREEMENT WITH FRESENIUS MEDICAL CARE.‍MERGER IS EXPECTED TO BE COMPLETED IN 2018​.ABOUT 94% OF VOTE CAST AT SPECIAL MEETING OF STOCKHOLDERS VOTED IN FAVOR OF ADOPTION OF MERGER AGREEMENT WITH FRESENIUS MEDICAL CARE​.  Full Article

NxStage Medical announces FDA clearance for solo home hemodialysis using NxStage system one
Monday, 28 Aug 2017 08:00am EDT 

Aug 28 (Reuters) - NxStage Medical Inc :NxStage Medical announces FDA clearance for solo home hemodialysis using NxStage® system one™.NxStage Medical Inc - ‍FDA has cleared its system one for solo home hemodialysis, without a care partner, during waking hours​.  Full Article

Nxstage Medical Inc says subsidiary is partnering with Dialyze Direct​
Friday, 11 Aug 2017 09:41am EDT 

Aug 11 (Reuters) - Nxstage Medical Inc :‍Nxstage kidney care subsidiary is partnering with Dialyze Direct​.  Full Article

NxStage Medical says if merger terminated, Fresenius Medical Care Holdings to pay termination fee of $100 mln- SEC Filing
Monday, 7 Aug 2017 04:53pm EDT 

Aug 7 (Reuters) - NxStage Medical Inc :NxStage Medical - if merger agreement terminated under certain circumstances,Fresenius Medical Care Holdings to pay co a termination fee of $100 million.  Full Article

NxStage Medical posts Q2 loss of $0.03 per share
Monday, 7 Aug 2017 02:15am EDT 

Aug 7 (Reuters) - Nxstage Medical Inc :NxStage reports second quarter financial results.Q2 revenue $96.2 million versus I/B/E/S view $96.5 million.NxStage Medical - in light of acquisition agreement between Fresenius Medical Care and NxStage, NxStage is no longer providing financial guidance.Has canceled its previously announced conference call to discuss its financial results for Q2 of 2017.Qtrly loss per share $0.03.  Full Article

NxStage Q1 revenue $96.8 million
Tuesday, 9 May 2017 08:16am EDT 

May 9 (Reuters) - NxStage Medical Inc ::NxStage reports first quarter financial results.Sees q2 2017 revenue $95 million to $97 million.Q1 revenue $96.8 million versus I/B/E/S view $95.3 million.NxStage Medical Inc - qtrly loss per share $ 0.02.NxStage Medical Inc - revising annual home revenue growth target to be between 10 to 13 pct for 2017 versus previous 15 pct target.NxStage Medical Inc - expect fy total company revenue in a range of $400 to $405 million.NxStage Medical Inc - company reaffirms total revenue guidance and profitability for 2017.NxStage Medical Inc - for q2 of 2017, company expects net loss in range of $1 to $3 million.Q2 revenue view $98.5 million -- Thomson Reuters I/B/E/S.Fy2017 revenue view $401.5 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.02 -- Thomson Reuters I/B/E/S.  Full Article

NxStage reports Q4 revenue of $93 million
Tuesday, 28 Feb 2017 08:02am EST 

NxStage Medical Inc : NxStage reports fourth quarter and full-year 2016 financial results . Q4 revenue $93 million versus I/B/E/S view $91.8 million . Sees FY 2017 revenue $400 million to $405 million . NxStage Medical Inc - Company continues to target introduction of peritoneal dialysis system at end of 2017 . NxStage Medical Inc - Company is forecasting revenue between $95 and $97 million for Q1 of 2017 . NxStage Medical Inc - Company also expects to have positive net income for full fiscal year 2017 . Qtrly loss per share $0.02 . NxStage Medical Inc - Sees net loss in range of $1 to $3 million for Q1 of 2017 . Q4 earnings per share view $-0.02 -- Thomson Reuters I/B/E/S .FY2017 revenue view $401.2 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-NXSTAGE SAYS STOCKHOLDER APPROVE MERGER WITH FRESENIUS MEDICAL CARE

* NXSTAGE ANNOUNCES STOCKHOLDER APPROVAL OF MERGER AGREEMENT WITH FRESENIUS MEDICAL CARE